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ABSTRACT 
Aims: Poor information is available on the molecular landscape characterizing the 
carcinogenetic process occurring in ampullary mucosa. MiR-21 is one of the most 
frequently up-regulated miRNAs in pancreatic adenocarcinoma, a tumor sharing 
similar molecular features with ampullary adenocarcinomas (AVCs). 
Methods: We have profiled, by in situ hybridization (ISH), miR-21 expression in a 
series of 26 AVCs, 50 ampullary dysplastic lesions and 10 normal duodenal mucosa 
samples. The same series was investigated by immunohistochemistry for β-catenin, 
p53 and HER2 expression HER2 gene amplification was evaluated by chromogenic 
in situ hybridization. To validate miR-21 ISH results we performed miR-21 qRT-PCR 
analysis in a series of 10 AVCs and their matched normal samples. 
Results: All the normal control samples showed a negative or faint miR-21 expression, 
whereas a significant miR-21 up-regulation was observed during the carcinogenetic 
cascade (p<0.001), with 21/26 (80.8%) of cancer samples showing a miR-21 
overexpression. In comparison to control samples, a significant overexpression was 
found in samples of LG-IEN (p= 0.0003), HG-IEN (p= 0.0001), and AVCs (p<0.0001). 
No significant difference in miR-21 overexpression was observed between LG-IEN, 
HG-IEN and AVCs. By qRT-PCR analysis, AVCs showed a 1.7-fold increase over the 
controls (p = 0.003). P53 was frequently dysregulated in both dysplastic and 
carcinoma samples (44 out of 76; 57.9%). A 20% (10/50) of dysplastic lesions and 
11% (3/26) of carcinomas were characterized by a nuclear localization of β-catenin. 
Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2+), 
which corresponded to a HER2 gene amplification at CISH analysis. 
Conclusions: This is the first study demonstrating a miRNA dysregulation in the whole 
spectrum of ampullary carcinogenesis. MiR-21 overexpression is an early molecular 
event during ampullary carcinogenesis and its levels increase with the neoplastic 
progression. 
  
INTRODUCTION 
Ampulla of Vater carcinomas (AVCs) represent a rare and heterogeneous group of 
cancers deriving from the ductal epithelium or intestinal mucosa of the papilla (1-4). 
AVCs have been categorized into two main histological subtypes: intestinal and 
pancreatobiliary (2, 5-8). Histological classification based on morphological feature 
fails to have a prognostic utility and the molecular pathogenesis of AVCs and of their 
pre-invasive lesions is still not well understood (9, 10). 
MicroRNAs (miRNAs) are short non-coding RNAs which regulate gene 
expression post-transcriptionally and are known to play important roles in 
oncogenesis, angiogenesis and tissue differentiation (11, 12). Among them, 
microRNA-21 (hsa-miR-21) has been originally described to be up-regulated in 
pancreatic adenocarcinoma (13, 14), and its overexpression has been related to 
decreased sensitivity to gemcitabine in vitro and with short survival in retrospective 
clinical studies (15-19). Moreover, this miRNA has emerged as a major driver of 
carcinogenesis in many different gastrointestinal settings (12, 20-27). 
Schultz and colleagues showed that microRNA expression profile in AVCs is 
very similar to pancreatic adenocarcinoma (28). However, despite recent extensive 
investigations, no information is available on miRNAs (and on miR-21 as well) 
dysregulation occurring with each phenotypic change involved in AVC carcinogenesis. 
In the present study, miR-21 expression was profiled by miRNA in situ 
hybridization (ISH) in a large series of formalin-fixed paraffin-embedded (FFPE) biopsy 
samples representing the whole spectrum of AVC oncogenesis. To validate obtained 
results we performed qRT-PCR in a series of 10 AVCs and their matched normal 
samples. Furthermore, the FFPE series was investigated for the expression of HER2, 
p53, and β–catenin in neoplastic epithelia. 
 
MATERIALS AND METHODS 
Cases 
A consecutive cohort of 50 ampullary adenomas and 26 adenocarcinomas (all 
Caucasian; M/F 40/36; mean age 62.4± 15.4) were retrospectively selected from the 
electronic archives of the Surgical Pathology Unit at Padua University. All patients 
involved in this study gave their informed written consent. The Helsinki Declaration 
and the international and institute's ethical regulations on research on human tissues 
were followed. The same series was previously investigated for PD-L1 expression 
(10). 
To be defined as AVC, a tumor should be characterized by an epicenter located: 
i) in the lumen or walls of the distal end of the common bile duct and/or pancreatic 
duct; ii) at the papilla of Vater; or iii) at the duodenal surface of the papilla (3, 8). 
The inclusion condition for this study was a concordant diagnosis among two 
gastrointestinal pathologists (MF and CL) based on morphological criteria of the WHO 
2010 classification (8) and immunohistochemical (CDX2 and MUC1) profiling (2). 
Samples were classified as: i) 46 intestinal-type adenoma (35 with low-grade dysplasia 
[low-grade intraepithelial neoplasia]; 11 with high-grade dysplasia [high-grade 
intraepithelial neoplasia]); ii) 4 non-invasive papillary neoplasm, pancreatobiliary type 
(all characterized by high-grade dysplasia); iii) 19 intestinal-type adenocarcinomas; 7 
pancreatobiliary-type adenocarcinoma. The intestinal-type adenomas were further 
categorized according their phenotype in tubular (n=35), tubulovillous (n=9), and 
villous (n=2). 
As normal control, 10 normal peri-papillary biopsy samples from patients 
underwent to upper endoscopy for dysfunctional dyspepsia were collected. Patients 
with Helicobacter pylori infection, and gastrointestinal polyposis were excluded from 
the study. 
 
Sample preparation and immunohistochemistry (IHC) 
All samples were processed using the Galileo CK3500 Arrayer (www.isenet.it), a 
semiautomatic and computer-assisted Tissue Macro Array (TMA) platform, as 
previously described (10, 29). 
IHC stainings were automatically performed using the Bond Polymer Refine 
Detection kit (Leica Biosystems, Newcastle Upon Tyne, UK) in the BOND-MAX system 
(Leica Biosystems) on 4 μm-thick FFPE sections with the primary antibodies for HER2 
(CB11; Leica; ready to use), β-catenin (17C2; Leica; 1:10), and p53 (EP9, Cell Marque, 
Rocklin, California; 1:50). 
IHC reaction for p53 was evaluated in percentage of nuclear staining in neoplastic 
cells; the results were dichotomized as negative (<50% of positive cells) and positive 
(≥50%) (30). β-catenin was considered positive in the presence of a nuclear staining 
in neoplastic epithelia. 
HER2 expression was evaluated with the score used for the characterization of 
gastric adenocarcinoma. To test HER2 gene amplification in IHC 2+ cases, an HER2 
chromogenic in situ hybridization (CISH) was performed according to the 
manufacturer’s protocol (DuoCISH kit, DakoCytomation, Glostrup, DK) (29, 31). 
 
miR-21 in situ hybridization 
In situ hybridization (ISH) was performed using the GenPoint™ Catalyzed Signal 
Amplification System (DakoCytomation) according to the manufacturer’s protocol. 
Briefly, slides were incubated at 60 °C for 30 min and deparaffinized (26, 29). Sections 
were treated with Proteinase K (DakoCytomation) for 30 min at room temperature, 
rinsed several times with dH2O, and immersed in 95% ethanol for 10 s before air-
drying. The slides were prehybridized at 49–56 °C for 1h with mRNA ISH buffer 
(Ambion) before overnight incubation at 49–56 °C in buffer containing the 5′-biotin-
labeled miR-21 miRCURY™ LNA detection probe (Exiqon, Woburn, MA, USA) or the 
scrambled negative control probe (U6, Exiqon) at a final concentration of 200 nM. The 
slides were washed in both Tris-buffered saline with Tween (TBST) and GenPoint™ 
stringent wash solution (54 °C for 30 min), then exposed to H2O2 blocking solution 
(DakoCytomation) for 20 min, and then further blocked in a blocking buffer 
(DakoCytomation) for 30 min before they were exposed to primary streptavidin–
horseradish peroxidase (HRP) antibody, biotinyl tyramide, secondary streptavidin–
HRP antibody, and DAB chromogen solutions, following the manufacturer’s protocol. 
The slides were then briefly counterstained in hematoxylin and rinsed with TBST and 
water before mounting. 
Only cytoplasmic miR-21 intensity in epithelial cells was retained for scoring 
purposes and cases were classified as: 0 = negative or faint expression in most cells; 
1+ = low expression in most cells or moderate expression in < 50% of the cells; 2+ = 
moderate to strong expression in most cells. 
 
Quantitative real-time polymerase chain reaction 
FFPE samples (10 AVCs and their matched normal duodenal mucosa samples) were 
deparaffinized with xylene at 50 °C for 3 min. Total RNA extraction was done using the 
RecoverAll kit (Ambion Inc, Austin, TX, USA) according to the manufacturer’s 
instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis 
was performed using the GeneAmp PCR 9700 thermocycler (Applied Biosystems, 
Foster City, CA, USA), and gene expression levels were quantified using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems) (26). 
The NCodeTM miRNA qRT-PCR method (Invitrogen, Carlsbad, CA, USA) was 
used to detect and quantify mature miR-21 (primer sequence: 5′-
CGGTAGCTTATCAGACTGATGTTGA-3′) according to the manufacturer’s 
instructions. Normalization was done with the small nuclear RNA U6B (Invitrogen). 
PCR reactions were run in triplicate, including no-template controls. The data were 
analyzed using the comparative CT method. 
 
Statistical analysis 
Differences between groups were tested by applying the paired t-test and chi-square 
test. To verify a hypothetical linear trend of miR-21 expression in neoplastic 
progression we performed a Cochran–Armitage test for trend. P values <0.05 were 
considered significant. The statistical analysis was performed using STATA software 
(Stata Corporation, College Station, TX). 
 
RESULTS 
Main histopathological and immunophenotypical features of the considered series are 
summarized in Table 1. 
All the 10 normal control samples showed a negative or faint miR-21 expression 
at ISH analysis, whereas a significant miR-21 up-regulation was observed during the 
carcinogenetic cascade (p<0.001), with 21/26 (80.8%) of cancer samples showing a 
miR-21 overexpression (Figures 1A & 2). 
In comparison to control samples, a significant overexpression was found in 
samples of LG-IEN (p= 0.0003), HG-IEN (p= 0.0001), and AVCs (p<0.0001). No 
significant difference in miR-21 overexpression was observed between LG-IEN, HG-
IEN and AVCs, even a higher miR-21 overexpression prevalence was observed in less 
differentiated lesions (LG-IEN 25/35 [71.4%] positive cases; HG-IEN 12/15 [80.0%] 
positive cases; AVCs 21/26 [80.8%] positive cases). This was even more evident for 
moderate to strong miR-21 overexpression (LG-IEN 6/35 [17.1%] positive cases; HG-
IEN 5/15 [33.3%] positive cases; AVCs 11/26 [42.3%] positive cases). 
To further confirm miR-21 overexpression in AVCs, we tested 10 samples with 
their normal matched mucosa by qRT-PCR analysis. AVCs showed a 1.7-fold increase 
over the controls (p = 0.003; Figure 1B). 
Confirming the central role of p53 alterations in biliary tract cancers (9, 32-34), 
44 out of 76 (57.9%) neoplastic samples showed p53 overexpression. Similar 
prevalence was observed among dysplastic and invasive samples; all control samples 
showed a regular p53 stain. 
Thirteen neoplastic cases (17.1%) were characterized by a nuclear localization 
of β-catenin: the 20% (10/50) of dysplastic lesions and the 11% (3/26) of carcinomas. 
The 3 AVCs with aberrant expression of β-catenin were intestinal type. 
Only two adenocarcinomas (7.7%; both intestinal-type) showed a HER2 
overexpression (both 2+), which corresponded to a HER2 gene amplification at CISH 
analysis. 
No significant correlation was observed between miR-21 overexpression and 
p53, β-catenin or HER2 dysregulation. 
 
DISCUSSION 
The normal and neoplastic mucosa overlaying the ampulla of Vater are both 
characterized by a heterogeneous histological commitment, which results into a 
difficult and limited histopathological categorization of AVCs. In spite of our well-
established understanding of the natural phenotypic history occurring in the 
progression from native epithelia to invasive carcinomas in the ampullary mucosa, little 
information is available on molecular pathogenesis. New molecular biomarkers are 
thus warranted to adequately stratify patients according to their risk of developing 
invasive cancer and to introduce targeted therapies based on a biological rationale. 
MiRNAs’ dysregulation play a leading role since early phases of 
(gastrointestinal) oncogenesis; furthermore they may influence tumor responsiveness 
to chemotherapy (35). Their relative stability in FFPE samples pinpointed this class of 
molecules as reliable biomarkers with potential diagnostic/prognostic implications to 
be introduced into clinical practice. 
Several studies have shown that miR-21 is one of the most frequently up-
regulated miRNAs in several type of cancers including pancreatic adenocarcinomas 
(15, 16, 18-21, 26, 27, 36-40). The oncogenic properties of miR-21 are further 
supported by functional studies showing that inhibition of miR-21 expression reduces 
proliferation and generates a pro-apoptotic and anti-angiogenesis response of several 
cancer cells lines (16, 17, 19). From a clinical point of view, its overexpression has 
been correlated with a poor clinical outcome and resistance to chemotherapy (15, 16, 
18, 37). 
To our knowledge, our study is the first that demonstrates dysregulation of miR-
21 in the whole spectrum of ampullary carcinogenesis. We were able to demonstrate 
that miR-21 overexpression is an early event in ampullary carcinogenesis and its 
levels increase with the neoplastic progression. 
Beside miRNAs’ dysregulation, two recent whole-exome sequencing studies 
(32, 41) confirmed previous literature findings on the most molecular alterations 
observed among AVCs, supporting a central role for five main molecular pathways: i) 
RAS/PI3K (HER2, KRAS, PIK3CA); ii) TGFβ (ELF3, SMAD4); iii) WNT (APC, 
CTNNB1); iv) p53 (CDKN2A, ATM, TP53); v) Chromatin remodeling (ARID2, ARID1A). 
Intestinal-type carcinomas are characterized by a molecular signature similar to what 
observed in colorectal cancer, whereas pancreatobiliary-type to that of pancreatic 
ductal adenocarcinoma (28, 32). However, a significant overlap with common 
mutations (KRAS, TP53, CTNNB1, SMAD4) were observed in both subtypes (42). 
We missed to find any relationship between miR-21 overexpression and p53, 
β-catenin or HER2 dysregulation. This could be explained by the relative low number 
of analyzed cases. However, our results are in line with the current Literature. 
The p53 oncosuppressor role is at the center of many cellular pathways that 
respond to DNA damage, improper mitogen stimulation, and cellular stress. The 
importance of p53 in carcinogenesis is indicated by the presence of mutations in the 
p53 pathway in nearly all cancers (43). In AVCs, p53 dysregulation occurs during 
malignant transformation from the adenoma and continues during the tumor 
progression in carcinoma. Moreover clinical prognosis of de novo carcinomas with p53 
overexpression was worse than that of the remaining patients (44). It has been shown 
that miR-21 suppresses p53-mediated apoptosis contributing to chemotherapy tumor 
resistance (43). 
β-catenin plays a critical role in cell-to-cell adhesion by linking cadherins to the 
actin cytoskeleton and regulate transcription in the WNT signaling pathway. Indeed, 
upon WNT activation, β-catenin is translocated from the membrane to the cytoplasm 
and nucleus, where it interacts with transcriptional activators to modulate a number of 
target genes associated with increased growth, invasion and cellular transformation, 
such as c-MYC or cyclin D1. Recently has been shown that miR‑21 upregulated the 
protein expression level of β‑catenin in glioma (45) and lung cancer cells (46) and 
increased CyclinD1 gene expression (46). Therefore β‑catenin may be an important 
downstream mediator of miR‑21 that allow to regulate proliferation, migration, invasion 
and resistance to chemotherapy of cancer cells. In fact APC/β-catenin is the most 
frequent genetic pathway underlying colon carcinogenesis and is associated with the 
classic adenoma-carcinoma sequence; this can confirm our finding that the 3 AVCs 
with aberrant expression of β-catenin were intestinal type. In addition we can postulate 
that also dysregulation of WNT/β‑catenin signaling pathway is an early event in 
ampullary carcinogenesis.  
In a recent NGS analysis of 32 AVCs the most frequently amplified gene was 
ERBB2 and approximately 13% of AVCs exhibit ERBB2 amplification, without 
predilection for subtype (42). On the other hand, in contrast to what observed in the 
gastroesophageal setting (47), no HER2 overexpression was observed in pre-invasive 
lesions. According to previous studies, we provide data correlating ERBB2 in situ 
hybridization and IHC results in AVCs. Obtained results confirm that the IHC scoring 
criteria used for gastric carcinoma work well for AVCs for predicting gene amplification. 
Furthermore a similar molecular profile to ERBB2-amplified gastric carcinoma, can 
represent a hypothetical benefit from similar targeted therapy but the significance of 
the ERBB2 amplification detected in this study is yet to be determined. 
In conclusion, we demonstrated an early involvement of miR-21, p53 and 
β‑catenin in ampullary carcinogenesis. Since miR-21 exerts its oncogenic function 
through a multi-pathways targeting, further larger and multi-centric studies should 
investigated the altered molecular cascades resulted from miR-21 early dysregulation 
to find novel reliable early biomarkers of ampullary mucosa transformation. 
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TABLE 1. Main pathological features of the considered series. 
 
Class # 
Histotype 
(Intestinal/
PB) 
miR-21  
p53 
(n; %) 
HER2 
(n; %) 
β-catenin 
(n; %) 0 
(n; %) 
1+ 
(n; %) 
2+ 
(n; %) 
Normal 10 - 
10/10 
(100.0%) 
0/10 
(0.0%) 
0/10 
(0.0%) 
0/10 
(0.0%) 
0/10 
(0.0%) 
0/10 
(0.0%) 
LG-IEN 35 35/0 
10/35 
(28.57%) 
19/35 
(54.28%) 
6/35 
(17.14%) 
20/35 
(57.1%) 
0/35 
(0.0%) 
7/35 
(20.0%) 
HG-IEN 15 11/4 
2/15 
(13.33%) 
8/15 
(53.33 %) 
5/15 
(33.33 %) 
7/15 
(46.7%) 
0/15 
(0.0%) 
3/15 
(20.0%) 
AVC 26 19/7 
5/26 
(19.23 %) 
10/26 
(38.46 %) 
11/26 
(42.30%) 
17/26 
(65.4%) 
2/26 
(7.7%) 
3/26 
(11.5%) 
 
Notes: PB= pancreatobiliary; LG-IEN= low-grade intraepithelial neoplasia; HG-IEN= high-grade intraepithelial neoplasia; AVC= 
Ampulla of Vater carcinoma; 
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Figure 1. (A) miR-21 expression distribution at in situ hybridization (ISH) 
analysis. (B) Consistent with the ISH results, miR-21 was significantly 
overexpressed by 1.7-fold in AVC tissues in comparison to matched normal 
mucosa by qRT-PCR. 
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Figure 2. Representative miR-21 ISH stainings during ampullary carcinogenesis. 
Normal duodenal mucosa showing none or weak miR-21 expression (A). LG-IEN 
(upper left over the dotted line) showing weak miR-21 expression, but higher 
expression in comparison with normal surrounding mucosa (lower right) (B). Two 
cases of HG-IEN showing moderate (1+) to strong (2+) miR-21 expression (C-D). 
Intestinal type AVC showing moderate miR-21 expression (E). The invasive front 
of an AVC (asterisk) showing strong expression in comparison to normal 
surrounding mucosa (F). Original magnifications 20x and 40x. LG-IEN= low-
grade intraepithelial neoplasia; HG-IEN= high-grade intraepithelial neoplasia; 
AVC= Ampulla of Vater carcinoma. 
